Oral Peptide Delivery

Oral peptide delivery means getting an intact peptide from a swallowed tablet into the systemic circulation, against three stacked barriers: gastric acid and pepsin, pancreatic and brush-border proteases, and an intestinal epithelium sealed by tight junctions and backed by efflux transporters that is built to admit small nutrients rather than molecules of several thousand daltons. The resulting arithmetic is brutal, since absolute bioavailability is typically well under one percent and the product must carry far more active material than an injection to reach the same exposure.

It is nevertheless solved for a few molecules. Oral semaglutide was approved by the FDA in 2019, co-formulated with the absorption enhancer SNAC, which raises local pH and promotes absorption across the gastric mucosa; bioavailability sits near one percent and falls sharply with food and fluid in the stomach. Oral octreotide for acromegaly followed in 2020 on different enhancer chemistry. Cyclosporine, a cyclic peptide, is orally active unaided because cyclisation and N-methylation hide its backbone from proteases.

The route trades a large rise in variability and in material cost for the removal of needles and injection-site reactions. Because absorption depends on gastric conditions, the same product in the same person can give noticeably different exposures day to day, which matters far more for a narrow therapeutic window than for a flat exposure-response curve.

The common misreading is treating any swallowed peptide product as orally delivered. Collagen peptide powders are digested to amino acids and short fragments, so their effects, if any, are nutritional rather than the action of the intact molecule. Grey-market capsules of research peptides carry no enhancer, no enteric protection and no human pharmacokinetic data.